Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

299
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
299
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

272
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
272
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

645
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
645
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

357
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
357

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enabling scale and spread of technology-enabled remote monitoring of blood pressure at home: findings from a rapid qualitative evaluation.

NIHR open research·2026
Same author

Abortion stigma among abortion providers in high-income countries: a mixed methods systematic review.

Sexual and reproductive health matters·2026
Same author

Effect of can damage on element migration into meat products during storage and the associated health risks.

Food chemistry·2026
Same author

Abortion stigma amongst the public in high-income countries: a mixed-method systematic review.

Sexual and reproductive health matters·2026
Same author

Gender Differences in Anti-Doping Rule Violations Based on a 19-Year Data Analysis from the Serbian Anti-Doping Agency: National Study.

Sports (Basel, Switzerland)·2025
Same author

Gender and mental health of adolescents: A conceptual framework developed in a Delphi study.

PloS one·2025

Related Experiment Video

Updated: Feb 21, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.2K

Hepatitis C: Understanding Factors That Influence the Physicians' Treatment Decisions.

Celine Miani, Catriona Manville, Peter Burge

    Rand Health Quarterly
    |October 7, 2017
    PubMed
    Summary

    Physicians weigh multiple factors when deciding on Hepatitis C (HCV) treatment, with thrombocytopenia significantly influencing choices across four European nations. Understanding these factors optimizes patient care pathways.

    Keywords:
    DecisionmakingFranceHepatitis CItalyPhysiciansSpainUnited Kingdom

    More Related Videos

    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
    04:11

    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

    Published on: December 15, 2023

    4.8K
    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.6K

    Related Experiment Videos

    Last Updated: Feb 21, 2026

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
    12:24

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

    Published on: September 30, 2021

    6.2K
    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
    04:11

    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

    Published on: December 15, 2023

    4.8K
    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.6K

    Area of Science:

    • Hepatology
    • Health Economics
    • Clinical Decision Making

    Background:

    • Hepatitis C (HCV) treatment decisions are complex, influenced by various clinical and systemic factors.
    • Understanding physician decision-making is crucial for optimizing HCV treatment pathways and patient outcomes.
    • Variations in healthcare systems across Europe may impact treatment accessibility and choices.

    Purpose of the Study:

    • To identify and analyze factors influencing physician decisions for Hepatitis C (HCV) treatment.
    • To assess the comparative importance and trade-offs of these factors, including thrombocytopenia.
    • To examine HCV patient journeys and identify potential deviations in four European countries.

    Main Methods:

    • Literature review and guideline analysis.
    • Key informant interviews with national experts.
    • Patient journey mapping across France, Italy, Spain, and the UK.
    • Discrete Choice Experiments (DCEs) to quantify factor importance.
    • Expert workshops to develop treatment challenge scenarios.

    Main Results:

    • Identified key clinical and systemic factors influencing HCV treatment decisions.
    • Quantified the impact of specific factors, including thrombocytopenia, on treatment choices.
    • Mapped patient journeys, highlighting potential points for intervention.
    • DCE results provided quantitative insights into physician preferences and trade-offs.

    Conclusions:

    • Physician decision-making in HCV treatment is multifactorial, involving a balance of clinical and resource-related considerations.
    • Thrombocytopenia emerges as a significant factor impacting treatment selection.
    • Understanding these decision-making dynamics is essential for improving HCV management strategies in diverse European healthcare settings.